Hepatorenal Syndrome

Although rifaximin was well-tolerated in patients with severe cirrhosis and ascites, it did not improve transplant-free survival and cirrhosis-related complications and “cannot be recommended” as antibiotic prophylaxis, a researcher noted.

Patients with hepatorenal syndrome type 1 and advanced acute-on-chronic liver failure had significantly greater incidence of respiratory failure and 90-day mortality when treated with terlipressin vs. placebo, according to research.

The FDA has announced approval of Terlivaz, a terlipressin injection formulation by Mallinckrodt plc., to treat patients with hepatorenal syndrome with rapid reduction in kidney function.

In this Healio Gastroenterology video exclusive, Arun J. Sanyal, MD, professor of medicine at Virginia Commonwealth University, discussed real-world data on patient characteristics, treatment and clinical response in hepatorenal syndrome.

In this exclusive video, Andrew Allegretti, MD, MSc, discussed a post hoc analysis assessing serum creatinine in patients treated with terlipressin for hepatorenal syndrome-acute kidney injury.

A speaker at the American Nephrology Nurses Association’s Nephrology Nursing Practice, Management & Leadership Conference discussed the development of AKI in patients who have hepatorenal syndrome or who use acetaminophen therapies.

In this exclusive video, Andrew Allegretti, MD, MSc, discusses his poster from The Liver Meeting Digital Experience that explored factors associated with response to terlipressin treatment in patients with hepatorenal syndrome.

In this exclusive video, Andrew Allegretti, MD, MSc, from Massachusetts General Hospital, discusses his poster from The Liver Meeting Digital Experience on hepatorenal syndrome and acute kidney injury in patients with liver disease.

Although the FDA accepted a new drug application for terlipressin to treat hepatorenal syndrome type 1, the agency has issued a complete response letter to Mallinckrodt plc stating that more data are required before the NDA can be approved.

FDA Cardiovascular and Renal Drugs Advisory Committee voted 8-7 to recommend approval of terlipressin for the treatment of hepatorenal syndrome type 1 in patients with cirrhosis.